Skip to main content
. 2016 Mar 9;311(2):F362–F372. doi: 10.1152/ajprenal.00579.2015

Fig. 8.

Fig. 8.

AKI vs. AKI treated with hydrogel containing IL-10 subcutaneously (SQ gel/IL-10). Twenty-eight days following AKI, compared with the untreated AKI cohort, the group treated on day 3 (arrow) with HA containing 5 μg of IL-10 injected subcutaneously on the dorsum (SQ gel/IL-10) exhibited a higher post-AKI day 1 serum Cr, but there was no difference in Cr on days 4 or 28 (A). There was a similar increase in day 1 serum BUN in the treatment group with a reduction seen on day 28 (B). There was no change in urine NGAL (C); however, serum IL-6 was reduced in the treatment group (D). Serum IL-10 was reduced in the treatment group (E). Lung MPO was unchanged (F). There was no change in fibrosis via Picrosirius Red staining in either the left or right kidneys of the treatment group (G). There was a reduction in collagen type III formation in both the left and right kidneys of the treatment group (H). There was a reduction in α-SMA in the right but not the left kidneys of the treatment group (I); n = 5, *P < 0.05.